COPCOV – Chloroquine/Hydroxychloroquine Prevention of Coronavirus Disease (COVID-19)

StudyFor two years, we’ve been living in the COVID-19 pandemic. This situation forced everything to adapt quickly, especially the healthcare field. Some medications, like a vaccine, usually need years to be approved. But again, COVID-19 played its ace, making them (COVID-19 vaccines) skip the queue and get reviewed earlier. Almost 4.78 billion people were fully vaccinated after the first vaccine was approved nearly a year ago. This has covered 61.3% of the population. Unfortunately, not everybody can get the vaccines regarding their condition. Thus, an alternative preventive measurement is needed to protect people from COVID-19 infection.

The term Chloroquine/Hydroxychloroquine might be unknown to some of us. Still, the footprint of this medicine was widely known to prevent malaria. Interestingly, a study found that Chloroquine and Hydroxychloroquine demonstrate an antiviral activity toward the SARS-CoV-2 virus. This finding shares hope for people who cannot be vaccinated due to certain conditions. High-risk people can benefit from those drug therapy as a preventive action against COVID-19.